Abstract: A method and apparatus for billing data services. A system that incorporates teachings of the present disclosure may include, for example, a system having a controller that manages a communications interface coupled to a communication system. The controller can be programmed to calculate a charge for service according to a degree of asymmetric bandwidth usage of upstream and downstream data traffic consumed by customer premise equipment. Additional embodiments are disclosed.

Abstract: A method and apparatus for billing data services. A system that incorporates teachings of the present disclosure may include, for example, a system having a controller that manages a communications interface coupled to a communication system. The controller can be programmed to calculate a charge for service according to a degree of asymmetric bandwidth usage of upstream and downstream data traffic consumed by customer premise equipment. Additional embodiments are disclosed.

Abstract: A system for securing a first tubular to a second tubular including a housing having at least one group of at least one window therein. A gripping assembly is disposed in the housing and has at least one member operatively arranged for selectably extending through the at least one window for internally gripping the first tubular. A coupling unit is included having a first clamping mechanism and a second clamping mechanism. The first clamping mechanism is operatively arranged for externally clamping the housing, and the second clamping mechanism is operatively arranged for externally clamping the second tubular component. A method of securing together two tubular components is also included.

Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1?is?GYSFTGYNMN VHCDR2?is?NIDPYYGGTTYNQKFKG VHCDR3?is?EVDY VLCDR1?is?RASKSVSTSTSGYSYMH VLCDR2?is?LVSNLES VLCDR3?is?QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.

Abstract: A method and apparatus for billing data services. A system that incorporates teachings of the present disclosure may include, for example, a system having a controller that manages a communications interface coupled to a communication system. The controller can be programmed to calculate a charge for service according to a degree of asymmetric bandwidth usage of upstream and downstream data traffic consumed by customer premise equipment (CPE). Additional embodiments are disclosed.

Abstract: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGHRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.

Abstract: A method and apparatus for billing data services. A system that incorporates teachings of the present disclosure may include, for example, a system having a controller that manages a communications interface coupled to a communication system. The controller can be programmed to calculate a charge for service according to a degree of asymmetric bandwidth usage of upstream and downstream data traffic consumed by customer premise equipment (CPE). Additional embodiments are disclosed.

Abstract: A method and apparatus for billing data services. A system that incorporates teachings of the present disclosure may include, for example, a system having a controller that manages a communications interface coupled to a communication system. The controller can be programmed to calculate a charge for service according to a degree of asymmetric bandwidth usage of upstream and downstream data traffic consumed by customer premise equipment (CPE). Additional embodiments are disclosed.

Abstract: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGHRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.

Abstract: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.

Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1?is?GYSFTGYNMN VHCDR2?is?NIDPYYGGTTYNQKFKG VHCDR3?is?EVDY VLCDR1?is?RASKSVSTSTSGYSYMH VLCDR2?is?LVSNLES VLCDR3?is?QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.

Abstract: A method and apparatus for billing data services. A system that incorporates teachings of the present disclosure may include, for example, a system having a controller that manages a communications interface coupled to a communication system. The controller can be programmed to calculate a charge for service according to a degree of asymmetric bandwidth usage of upstream and downstream data traffic consumed by customer premise equipment (CPE). Additional embodiments are disclosed.

Abstract: An alignment apparatus for use with the assembly of tubular segments with a tubular string in a well bore is disclosed. The alignment apparatus includes an actuator assembly functionally associated with an engagement assembly. Upon actuation of the actuator assembly, the engagement assembly engages the segment. The alignment apparatus is then lowered such that the segment contacts the string, and a connection may be made. A method of improving the alignment of the segment with the tubular string in the well bore is also is also disclosed.

Abstract: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.

Abstract: The present invention relates to a novel hybridoma cell line which secretes monoclonal antibodies capable of binding to the AT1 subtype of the Angiotensin II receptor. It also relates to monoclonal antibodies secreted by the hybridoma, which antibodies may be used in diagnostic test kits as well as having therapeutic applications.

Abstract: The present invention relates to a novel hybridoma cell line which secretes monoclonal antibodies capable of binding to the AT.sub.1 subtype of the Angiotensin II receptor. It also relates to monoclonal antibodies secreted by the hybridoma, which antibodies may be used in diagnostic test kits as well as having therapeutic applications.